Annual sales, profits jump at AstraZeneca
AstraZeneca Plc posted a spike in full-year revenues and earnings on Tuesday, boosted by strong demand for its cancer drugs, and forecast further growth in the current year.
The blue chip heavyweight saw total revenues in the year to December end rise 9%, or by 8% on a constant currency basis, to $58.7bn. Core earnings per share were 11% stronger in constant currencies at $9.16. Both figures were largely in line with expectations.
AstraZeneca, which earlier this month started trading on the New York Stock Exchange alongside its London and Stockholm listings, said it had seen growth across divisions, including rare disease and cardiovascular, renal and metabolism.
However, the biggest growth was seen in the pharma's dominant oncology division, where revenues jumped 17% to $25.6bn.
Pascal Soriot, chief executive, said: "We saw strong commercial performance across our therapy areas and excellent pipeline delivery.
"The momentum across our company is continuing in 2026, and we are looking forward to the results of more than 20 phase 3 trial readouts this year."
The firm is currently predicting total revenues to increase by a mid-to-high single digit percentage in 2026, and core EPS by a low double-digit percentage.
The company is currently focused on boosting its presence in both the US and China, with multi-billion investments announced last year for both countries.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
